1. Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study
- Author
-
A. I. Espadana, Isabel Cano, Eliana Aguilar, Belén Vidriales-Vicente, Mar Tormo, Mercedes Colorado-Araujo, David Martínez-Cuadrón, Jorge Labrador Gómez, Pau Montesinos Fernandez, Celina Benavente, José A. Pérez-Simón, Raimundo García-Boyero, Cristina Gil, María Teresa López, María del Pilar Martínez-Sánchez, Jose Luis López-Lorenzo, Teresa Bernal del Castillo, Juan M. Bergua-Burgues, Rosa Fernández, MªJose Sayas-Lloris, Ma Luz Amigo, Esperanza Lavilla-Rubira, Pilar Herrera-Puente, Claudia Lucia Sossa-Melo, Josefina Serrano-López, María García-Fortes, Carlos Rodríguez-Medina, and Gabriela Rodríguez
- Subjects
Cancer Research ,medicine.medical_specialty ,Registry study ,Intensive chemotherapy ,03 medical and health sciences ,0302 clinical medicine ,Elderly ,Internal medicine ,medicine ,Overall survival ,Acute myeloid leukemia ,business.industry ,Cancer ,Hematology ,medicine.disease ,Prognosis ,Confidence interval ,Oncology ,030220 oncology & carcinogenesis ,Cohort ,Myeloid leukaemia ,business ,Acute myeloblastic leukaemia ,030215 immunology - Abstract
Selection of elderly patients (aged =60 years) for intensive chemotherapy treatment of acute myeloblastic leukaemia (AML) remains challenging. Several cooperative groups such as Acute Leukaemia French Association (ALFA), Haematological Oncology Clinical Studies Group (HOCSG) and MD Anderson Cancer Center (MDACC) have developed predictive models to select those patients who can benefit from intensive chemotherapy. Our purpose is to validate and compare these three models in a cohort of patients treated in real-life setting. For this, a total of 1724 elderly AML patients and treated with intensive chemotherapy regimens were identified in the PETHEMA registry. Median age was 67.2 years (range, 60-84,9) and median overall survival [OS] 9 months (95 % confidence interval [CI], 8.2-9.7). Taking into account the ALFA group's model, patients likely to benefit from intensive chemotherapy had longer OS (14 months, 95 % CI 12.3-15.7) than those unlikely to benefit (5 months, 95 % CI 4.1-5.9; p
- Published
- 2020